Morgan Stanley Maintains Overweight on Arcus Biosciences, Lowers Price Target to $22

Benzinga · 6d ago
Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target from $24 to $22.